ストックスクリーナーアプリを入手
2.0959
2.24%
0.0459
前日終値:
$2.05
開ける：
$2.0959
24時間の取引高:
652
Relative Volume:
0.08
時価総額：
$2.96M
収益：
-
当期純損益:
$-8.22M
株価収益率:
-0.2815
EPS:
-7.4459
ネットキャッシュフロー:
$-4.78M
1週間 パフォーマンス:
-3.86%
1か月 パフォーマンス:
-19.08%
6か月 パフォーマンス:
-39.70%
1年 パフォーマンス:
-51.93%
1日の値動き範囲:
$2.0959
$2.0959
1週間の範囲:
$2.05
$2.235
52週間の値動き範囲:
$1.84
$5.38
Synaptogenix Inc Stock (SNPX) Company Profile
名前
Synaptogenix Inc
セクター
電話
(973) 242-0005
住所
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
SNPX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNPX
Synaptogenix Inc
|
2.0959 | 2.96M | 0 | -8.22M | -4.78M | -7.4459 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Synaptogenix Inc (SNPX) 最新ニュース
Synaptogenix stock plunges to 52-week low of $2.14 By Investing.com - Investing.com Canada
Synaptogenix stock plunges to 52-week low of $2.14 - Investing.com Australia
Synaptogenix Inc. (SNPX) reports earnings - qz.com
Will Synaptogenix Make A Mark In Synaptic Regeneration? - RTTNews
Synaptogenix stock hits 52-week low at $2.15 amid market challenges - Investing.com Australia
Synaptogenix stock hits 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Synaptogenix (NASDAQ:SNPX) Trading Down 0.3% – Here’s Why - Defense World
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary - Benzinga
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.18% - MSN
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
Synaptogenix Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - Marketscreener.com
Synaptogenix (SNPX) Extends CEO’s Employment and Forms Special Committee to Explore Strategic Opportunities - Defense World
Synaptogenix forms committee to explore strategic opportunities - Investing.com
Synaptogenix forms committee to explore strategic opportunities By Investing.com - Investing.com South Africa
Synaptogenix Restructures Leadership Amid Strategic Refocus - TipRanks
Synaptogenix Forms Special Committee to Explore Strategic Options with $19.6M Cash Runway - StockTitan
Synaptogenix shareholders approve key proposals at annual meeting - Investing.com India
Synaptogenix shareholders approve key proposals at annual meeting By Investing.com - Investing.com Canada
Synaptogenix stock hits 52-week low at $2.71 amid market challenges - Investing.com
SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 - MSN
Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com
Synaptogenix Announces $5.0 Million Financing - citybiz
Polyrizon Stock Price, Quotes and Forecasts | NASDAQ:PLRZ - Benzinga
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena
Synaptogenix announces reverse stock split to regain Nasdaq compliance By Investing.com - Investing.com South Africa
Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Markets Insider
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders - PR Newswire
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The TechnionIsrael Institute of Technology - PR Newswire
'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial - OutSourcing-Pharma.com
Advanced Alzheimer's: Bryostatin-1 may be safe, effective - Medical News Today
Bryostatin found to slow cognitive decline in advanced Alzheimer's... - Alzheimer's News Today
Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the MarketAzafaros A.G., Cyclo Therapeutics, Inc., ZevraDenmark, Genzyme, IntraBio Inc, Mandos Health - PR Newswire
Best Penny Stocks To Buy Now? 10 Under $1 To Watch - Penny Stocks
Best Penny Stocks To Buy Now? 3 Under $1 To Watch - Penny Stocks
Phase 1 trial of bryostatin-1 in MS expected by year's end |... - Multiple Sclerosis News Today
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix reports data from Phase II Alzheimer’s trial - Clinical Trials Arena
Synaptogenix's Alzheimer's prospect flops in NIH-sponsored study, sinking stock - Fierce Biotech
Theriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News Summary - Benzinga
Roche's drug failure extends long list of Alzheimer's trial setbacks - Reuters.com
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital - Business Wire
Synaptogenix Announces Corporate Update Conference Call - StockTitan
Synaptogenix Inc (NASDAQ: SNPX) Announces a Peer-reviewed Paper on Bryostatin - BP Journal
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment - Seeking Alpha
Allarity Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ALLR - Benzinga
Quoin Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:QNRX - Benzinga
Synaptogenix Inc (SNPX) 財務データ
収益
当期純利益
現金流量
EPS
1.00%
大文字化:
|
ボリューム (24 時間):